Table 3.
Baseline characteristics of Cushing’s disease patients according to therapeutic response to ketoconazole.
| Controlled/partially controlled | Uncontrolled | p | ||
|---|---|---|---|---|
| Sex (F/M) | 17/8 (68/32%) | 7/1 (87.5/12.5%) | 0.2281 | |
| Initial UFC (times > ULN) |
0.62 ± 0.41 (-0.71–0.73) | 5.3 ± 8.21 (-0.14–34) | < 0.005 | |
| Final UFC (times > ULN) |
-0.48 ± 0.55 (-0.99–1.3) | 5.13 ± 6.58 (-0.09–19.9) | < 0.005 | |
| ACTH | 83.6 ± 81.8 (20–300) | 172.3 ± 408.2 (1–1696) | 0.635 | |
| Basal cortisol | 18.8 ± 9.5 (8.1–43) | 26.5 ± 12.39 (5.8–47) | 0.092 | |
| BMI | 34.5 ± 7.6 (25.8–48) | 31.3 ± 6.5 (23.6–50.4) | 0.268 | |
| Final dose | 468 ± 314 (0–1,000) | 562 ± 184 (300–800) | 0.576 | |
| Fasting blood glucose | 111.5 ± 39.9 (69–177) | 120.7 ± 46.4 (77–219) | 0.881 | |
| Prior TSS (Y/N) | 22/3 (88/12%) | 4/4 (50/50%) | 0.043 | |
| RDT (Y/N) | 9/16 (36/64%) | 2/6 (25/75%) | 0.56 | |
| Regular use (Y/N) | 23/2 (92/8%) | 6/2 (75/25%) | 0.2 | |
ACTH, adrenocorticotropic hormone; TSS, transsphenoidal surgery; RDT, radiotherapy; UFC, urinary free cortisol; ULN, upper limit of normal.